These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44 related articles for article (PubMed ID: 11824001)
21. Reteplase: a review of its use in the management of thrombotic occlusive disorders. Simpson D; Siddiqui MA; Scott LJ; Hilleman DE Am J Cardiovasc Drugs; 2006; 6(4):265-85. PubMed ID: 16913828 [TBL] [Abstract][Full Text] [Related]
22. The role of thrombolytic drugs in the management of myocardial infarction. Comparative clinical trials. Weaver WD Eur Heart J; 1996 Dec; 17 Suppl F():9-15. PubMed ID: 8960443 [TBL] [Abstract][Full Text] [Related]
23. New developments in thrombolytic therapy. Collen D; Gold HK Adv Exp Med Biol; 1990; 281():333-54. PubMed ID: 2129372 [TBL] [Abstract][Full Text] [Related]
24. Thrombolysis in acute myocardial infarction: analysis of studies comparing accelerated t-PA and streptokinase. Smith BJ J Accid Emerg Med; 1999 Nov; 16(6):407-11. PubMed ID: 10572811 [TBL] [Abstract][Full Text] [Related]
25. The concept of equivalence and its application to the assessment of thrombolytic effects. Hampton JR Eur Heart J; 1997 Dec; 18 Suppl F():F22-7. PubMed ID: 9447337 [TBL] [Abstract][Full Text] [Related]
26. Reteplase: a new thrombolytic for the treatment of acute myocardial infarction. Wooster MB; Luzier AB Ann Pharmacother; 1999 Mar; 33(3):318-24. PubMed ID: 10200858 [TBL] [Abstract][Full Text] [Related]
28. Reperfusion therapy for acute myocardial infarction. Which strategy for which patient? Boersma E; Steyerberg EW; Van der Vlugt MJ; Simoons ML Drugs; 1998 Jul; 56(1):31-48. PubMed ID: 9664197 [TBL] [Abstract][Full Text] [Related]
29. Thrombolytic therapy in Europe: current status. Vahanian A Eur Heart J; 1996 Sep; 17 Suppl E():21-7. PubMed ID: 11824000 [TBL] [Abstract][Full Text] [Related]
30. TIMI grade flow, mortality, and the GUSTO-III trial. Stringer KA Pharmacotherapy; 1998; 18(4):699-705. PubMed ID: 9692644 [TBL] [Abstract][Full Text] [Related]
31. Superiority and equivalence in thrombolytic drugs: an interpretation. Walley T; Dundar Y; Hill R; Dickson R QJM; 2003 Feb; 96(2):155-60. PubMed ID: 12589013 [No Abstract] [Full Text] [Related]
32. [Comparison of clinical efficacy of thrombolytic drugs in patients with acute myocardial infarction]. López-Sendón JL Rev Esp Cardiol; 1992; 45 Suppl 2():9-20. PubMed ID: 1475514 [TBL] [Abstract][Full Text] [Related]
33. Acylated plasminogen-streptokinase activator complex: a new approach to thrombolytic therapy. Crabbe SJ; Grimm AM; Hopkins LE Pharmacotherapy; 1990; 10(2):115-26. PubMed ID: 2140889 [TBL] [Abstract][Full Text] [Related]
34. Clinical trials in thrombolytic therapy, Part 2: The open-artery hypothesis and RAPID-1 and RAPID-2. Lopez LM Am J Health Syst Pharm; 1997 Nov; 54 Suppl 1():S27-30. PubMed ID: 9397235 [TBL] [Abstract][Full Text] [Related]
35. Potential cost effectiveness of tissue plasminogen activator among patients previously treated with streptokinase. Massel D Can J Cardiol; 1999 Feb; 15(2):173-9. PubMed ID: 10079776 [TBL] [Abstract][Full Text] [Related]
37. Current clinical use of reteplase for thrombolysis. A pharmacokinetic-pharmacodynamic perspective. Martin U; Kaufmann B; Neugebauer G Clin Pharmacokinet; 1999 Apr; 36(4):265-76. PubMed ID: 10320949 [TBL] [Abstract][Full Text] [Related]
38. Clinical trial results with a new plasminogen activator. Bode C; Peter K; Moser M; Smalling RW; Weaver WD Eur Heart J; 1997 Dec; 18 Suppl F():F17-21. PubMed ID: 9447336 [TBL] [Abstract][Full Text] [Related]
39. A perspective on the regulation of the evaluation of new antithrombotic drugs. Califf RM Am J Cardiol; 1998 Oct; 82(8B):25P-35P. PubMed ID: 9809889 [TBL] [Abstract][Full Text] [Related]
40. Mega-trials and equivalence trials: experience from the INJECT study. Hampton JR Eur Heart J; 1996 Sep; 17 Suppl E():28-34. PubMed ID: 11824001 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]